WCN26-5325 APIXABAN AND VASCULAR ACCESS THROMBOSIS IN DIALYSIS: A COMPARATIVE BEFORE-AND-AFTER ANALYSIS

Read full text Summarise with VIRAT
Authors: Mohamed Abdelaziz, Amna M. Alkalkami, Ayman Sabri Moussa, Ibrahim Jubran, Udeme E. Ekrikpo, Saad S. Alobaili
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Vascular access dysfunction is a major cause of morbidity in end-stage kidney disease (ESKD) patients on maintenance hemodialysis. Arteriovenous fistulas (AVF) and grafts (AVG), although preferred access types, are frequently compromised by recurrent thrombosis, leading to access failure and increased healthcare utilization and costs. Apixaban, a direct oral anticoagulant (DOAC), widely prescribed for atrial fibrillation and venous thromboembolism, has emerging off-label use in dialysis patients.

Fields of Study & Subjects

Central Venous Catheters and Hemodialysis Atrial Fibrillation Management and Outcomes Renal and Vascular Pathologies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105263–105263
Publication date
25 March 2026
Language
EN